Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Sensorion SA Stock

Price
Target price
€0.30

€0.30

8.460%
0.023
8.460%
-
 
11.12.25 / Stuttgart Stock Exchange WKN: A14SVV / Name: Sensorion SA / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Sensorion SA in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Sensorion SA is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Sensorion SA

sharewise wants to provide you with the best news and tools for Sensorion SA, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 08.12.25
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 17.09.25
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 15.08.25
Sensorion Announces Its Participation In Upcoming Investor Conferences
Sensorion Announces Its Participation In Upcoming Investor Conferences


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 31.07.25
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial


Regulatory News:



Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 29.07.25
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

BusinessWire_EN 
0 01.07.25